Chen et al. observed an objective response in a mixed non-ccRCC cohort treated with Nivolumab and CAB in papillary RCC 5/6 patients with NF2 or FH gene mutation. This evidence concerns the gene NF2 and nonpapillary renal cell carcinoma.